HomeCompareCYCCP vs SPHD

CYCCP vs SPHD: Dividend Comparison 2026

CYCCP yields 5.94% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHD wins by $5.8K in total portfolio value
10 years
CYCCP
CYCCP
● Live price
5.94%
Share price
$5.05
Annual div
$0.30
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.7K
Annual income
$0.61
Full CYCCP calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — CYCCP vs SPHD

📍 SPHD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYCCPSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYCCP + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYCCP pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYCCP
Annual income on $10K today (after 15% tax)
$504.95/yr
After 10yr DRIP, annual income (after tax)
$0.52/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, SPHD beats the other by $485.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYCCP + SPHD for your $10,000?

CYCCP: 50%SPHD: 50%
100% SPHD50/50100% CYCCP
Portfolio after 10yr
$23.6K
Annual income
$285.97/yr
Blended yield
1.21%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYCCP buys
0
SPHD buys
0
No recent congressional trades found for CYCCP or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYCCPSPHD
Forward yield5.94%4.33%
Annual dividend / share$0.30$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%0%
Portfolio after 10y$20.7K$26.5K
Annual income after 10y$0.61$571.32
Total dividends collected$604.00$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CYCCP vs SPHD ($10,000, DRIP)

YearCYCCP PortfolioCYCCP Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$10,997$297.03$11,133$432.85$136.00SPHD
2$11,919$152.64$12,363$450.36$444.00SPHD
3$12,831$77.31$13,695$467.39$864.00SPHD
4$13,768$38.89$15,138$483.90$1.4KSPHD
5$14,751$19.50$16,697$499.88$1.9KSPHD
6$15,794$9.76$18,382$515.31$2.6KSPHD
7$16,904$4.88$20,198$530.17$3.3KSPHD
8$18,090$2.44$22,157$544.46$4.1KSPHD
9$19,358$1.22$24,266$558.18$4.9KSPHD
10$20,713$0.61$26,536$571.32$5.8KSPHD

CYCCP vs SPHD: Complete Analysis 2026

CYCCPStock

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Full CYCCP Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this CYCCP vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYCCP vs SCHDCYCCP vs JEPICYCCP vs OCYCCP vs KOCYCCP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.